Join the Upcoming Conference Call by Apellis Pharmaceuticals
On October 30, 2025, Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) will host an important conference call at 8:30 a.m. ET to delve into their financial performance for the third quarter of 2025. This event presents investors and stakeholders with a valuable opportunity to hear directly from the company's leadership about their recent accomplishments and future outlook.
How to Participate in the Conference Call
Participants interested in joining the live call via phone are encouraged to pre-register for the event. This ensures a smooth experience with the ability to engage and ask questions. Additionally, a live audio webcast, including slides from the presentation, will be available on Apellis Pharmaceuticals’ official website under the “Events and Presentations” section in the “Investors and Media” area. If you miss the live event, a playback option will be available for 90 days following the presentation.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals stands at the forefront of biopharmaceutical innovation, specializing in complement science aimed at developing transformative therapies for serious diseases. The company is renowned for introducing a new class of complement medicine, marking a significant advancement in medical treatment with two approved C3-targeting therapies that address four critical diseases. A notable highlight includes the launch of the first-ever therapy for geographic atrophy, a leading cause of blindness, along with groundbreaking treatments for rare kidney diseases affecting patients aged 12 and older.
Focus on Innovation and Patient Care
Apellis is continuously striving to unlock additional potential therapies targeting C3, demonstrating a commitment to addressing unmet medical needs. This dedication reflects their vision of enhancing patient outcomes through innovative solutions.
Stay Connected with Apellis
To learn more about Apellis Pharmaceuticals and their ongoing research and developments, you can visit their website. Follow their journey on LinkedIn and other social media platforms to stay updated on their latest news and breakthroughs.
Investor Relations Contact
For any inquiries or further information, please reach out to Eva Stroynowski at Apellis Pharmaceuticals. You can contact her via email or by phone at 617.938.6229.
Frequently Asked Questions
What is the purpose of the conference call on October 30, 2025?
The conference call is intended to discuss the third quarter financial results of Apellis Pharmaceuticals and provide insights into their strategic direction.
How can I access the conference call?
You can access the conference call by pre-registering for the phone line or by visiting the company's website for the audio webcast.
Who should attend the call?
Investors, analysts, and stakeholders interested in the financial performance and strategy of Apellis Pharmaceuticals are encouraged to attend.
What recent breakthroughs has Apellis achieved?
Apellis has made significant strides in complement medicine, including therapies for geographic atrophy and rare kidney diseases.
How can I stay informed about Apellis Pharmaceuticals?
You can stay updated by visiting their official website and following them on social media channels like LinkedIn.
